 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Frits Van Rhee and Asis Shrestha.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.409 |
|
|
|
-
Shrestha A, Alzubi M, Alrawabdeh J, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Al Hadidi S. B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma. EJHaem. 2024 Jun; 5(3):554-559.
Score: 0.230
-
Mohan M, Szabo A, Cheruvalath H, Clennon A, Bhatlapenumarthi V, Patwari A, Balev M, Bhutani D, Shrestha A, Thanendrarajan S, Dhakal B, Zangari M, Trikannad A, Vellanki S, Al-Hadidi S, Lentzsch S, van Rhee F, Bag A, D'Souza A, Shah N, Chakraborty R, Shah MR, Schinke C. Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma. Blood Cancer J. 2025 Apr 23; 15(1):74.
Score: 0.062
-
Akhtar OS, Szabo A, Bhatlapenumarthi V, Forsberg M, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Patel T, Shrestha A, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, Shah MR, Bag A, D'Souza A, Schinke C, Chakraborty R, Shah N, Mohan M. Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies. Br J Haematol. 2024 Nov; 205(5):1830-1834.
Score: 0.059
-
Naqvi S, Shrestha A, Alzubi M, Alrawabdeh J, Thanendrarajan S, Zangari M, van Rhee F, Schinke C, Al Hadidi S. Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab. EJHaem. 2024 Aug; 5(4):789-792.
Score: 0.058
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|